CNCE Concert Pharmaceuticals, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

CNCE [NASD]

Concert Pharmaceuticals, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-3.07	Insider Own	3.60%	Shs Outstand	29.11M	Perf Week	8.85%
Market Cap	301.59M	Forward P/E	-	EPS next Y	-3.34	Insider Trans	-0.72%	Shs Float	24.36M	Perf Month	4.02%
Income	-76.80M	PEG	-	EPS next Q	-0.69	Inst Own	67.50%	Short Float	3.15%	Perf Quarter	6.21%
Sales	0.08M	P/S	3817.60	EPS this Y	-37.30%	Inst Trans	0.42%	Short Ratio	5.25	Perf Half Y	2.33%
Book/sh	5.31	P/B	1.90	EPS next Y	-9.40%	ROA	-47.80%	Target Price	-	Perf Year	-10.55%
Cash/sh	5.44	P/C	1.85	EPS next 5Y	-	ROE	-60.40%	52W Range	5.36 - 13.09	Perf YTD	9.38%
Dividend	-	P/FCF	-	EPS past 5Y	-10.40%	ROI	-77.80%	52W High	-21.54%	Beta	0.90
Dividend %	-	Quick Ratio	11.90	Sales past 5Y	-34.00%	Gross Margin	-	52W Low	91.60%	ATR	0.82
Employees	70	Current Ratio	11.90	Sales Q/Q	-99.30%	Oper. Margin	-	RSI (14)	54.93	Volatility	9.59% 8.35%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	24.20%	Profit Margin	-	Rel Volume	0.51	Prev Close	10.09
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Apr 30 BMO	Payout	-	Avg Volume	145.92K	Price	10.27
Recom	1.90	SMA20	1.35%	SMA50	7.16%	SMA200	15.97%	Volume	14,983	Change	1.78%

Mar-30-20

Initiated

Jefferies

Buy

$23

Oct-03-19

Reiterated

H.C. Wainwright

Buy

$29 → $25

Jun-24-19

Initiated

SunTrust

Buy

$30

Jun-13-19

Upgrade

Janney

Neutral → Buy

Jun-13-19

Reiterated

H.C. Wainwright

Buy

$26 → $29

Sep-13-18

Initiated

Janney

Neutral

Mar-09-18

Upgrade

Mizuho

Neutral → Buy

$23 → $27

Jan-12-18

Downgrade

Mizuho

Buy → Neutral

$23

Oct-26-17

Initiated

Mizuho

Buy

$23

Jul-24-17

Initiated

H.C. Wainwright

Buy

$20

Mar-07-17

Reiterated

Stifel

Buy

$21 → $31

Jul-01-16

Initiated

Stifel

Buy

$23

Sep-22-15

Reiterated

ROTH Capital

Buy

$22 → $32

Aug-12-15

Initiated

Brean Capital

Buy

$21

Nov-12-14

Reiterated

ROTH Capital

Buy

$28 → $21

Mar-10-14

Initiated

UBS

Buy

$25

Jul-08-20 07:00AM	Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata Business Wire +5.71%
Jul-06-20 11:44AM	Need To Know: Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Insiders Have Been Buying Shares Simply Wall St. +6.15%
09:30AM	Hedge Fund Sentiment Is Stagnant On Concert Pharmaceuticals Inc (CNCE) Insider Monkey
Jun-30-20 12:00PM	Concert (CNCE) Upgraded to Buy: Here's Why Zacks +5.18%
11:30AM	Is Concert Pharmaceuticals (CNCE) Stock Outpacing Its Medical Peers This Year? Zacks
Jun-24-20 10:39AM	Insider Sells Concert Pharmaceuticals' Shares Benzinga -5.80%
Jun-12-20 04:01PM	Concert Pharmaceuticals Releases Additional Data from Phase 2 Clinical Trial of CTP-543 in Alopecia Areata Business Wire +7.31%
May-26-20 07:00AM	Concert Pharmaceuticals to Webcast Fireside Chat at Jefferies Virtual Global Healthcare Conference Business Wire
May-22-20 08:52AM	How Concert Pharmaceuticals (CNCE) Stock Stands Out in a Strong Industry Zacks
May-12-20 09:14PM	Edited Transcript of CNCE earnings conference call or presentation 30-Apr-20 12:30pm GMT Thomson Reuters StreetEvents -5.37%
07:00AM	Concert Pharmaceuticals to Webcast Presentation at UBS Virtual Healthcare Conference Business Wire
May-01-20 12:30AM	Concert Pharmaceuticals, Inc. (CNCE) Q1 2020 Earnings Call Transcript Motley Fool -16.23%
Apr-30-20 08:45AM	Concert Pharmaceuticals (CNCE) Reports Q1 Loss, Lags Revenue Estimates Zacks -11.99%
07:00AM	Concert Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Update on Clinical Programs Business Wire
Apr-29-20 12:00PM	Concert (CNCE) Moves to Buy: Rationale Behind the Upgrade Zacks +8.21%
Apr-23-20 07:00AM	Concert Pharmaceuticals to Report First Quarter 2020 Financial Results on April 30, 2020 Business Wire
Apr-15-20 08:55AM	Why Concert Pharmaceuticals (CNCE) Stock Might be a Great Pick Zacks -5.87%
Apr-01-20 07:00AM	Concert Pharmaceuticals Announces Plans for CTP-543 Phase 3 Trials in Alopecia Areata Business Wire -11.54%
Mar-26-20 11:54AM	Some Concert Pharmaceuticals (NASDAQ:CNCE) Shareholders Are Down 47% Simply Wall St. +5.13%
Mar-12-20 12:13AM	Edited Transcript of CNCE earnings conference call or presentation 27-Feb-20 1:30pm GMT Thomson Reuters StreetEvents -5.99%
Feb-24-20 07:00AM	Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at the 2020 American Academy of Dermatology Annual Meeting Business Wire
Feb-20-20 07:00AM	Concert Pharmaceuticals to Report Full Year 2019 Results on February 27, 2020 Business Wire -5.04%
Jan-30-20 04:01PM	Concert Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Jan-28-20 09:00AM	Concert Pharmaceuticals Announces Pricing of Public Offering Business Wire +9.83%
Jan-27-20 04:02PM	Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire -8.61%
04:01PM	Concert Pharmaceuticals Announces Federal Circuit Granted its Motion to Vacate and Remand PTAB Decision Involving CTP-543 Business Wire
Jan-24-20 05:52AM	Should You Be Concerned About Concert Pharmaceuticals, Inc.'s (NASDAQ:CNCE) Historical Volatility? Simply Wall St. -15.00%
Jan-22-20 08:40AM	Concert Pharmaceuticals Announces Notice of Allowance for U.S. Patent Application Related to CTP-543, Lead Candidate for Treatment of Alopecia Areata Business Wire +33.03%
Dec-19-19 04:05PM	Concert Pharmaceuticals Successfully Completes Open Label Trial of CTP-543 in Patients with Alopecia Areata Business Wire
Dec-16-19 05:54AM	We Think Concert Pharmaceuticals (NASDAQ:CNCE) Needs To Drive Business Growth Carefully Simply Wall St.
Dec-13-19 02:18PM	Do Hedge Funds Love Concert Pharmaceuticals Inc (CNCE)? Insider Monkey
Dec-02-19 07:00AM	Concert Pharmaceuticals Initiates CTP-692 Phase 2 Trial in Schizophrenia Business Wire
Nov-25-19 11:21PM	Edited Transcript of CNCE earnings conference call or presentation 7-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-12-19 07:00AM	Concert Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire +6.63%
Nov-10-19 08:40AM	Should You Worry About Concert Pharmaceuticals, Inc.'s (NASDAQ:CNCE) CEO Salary Level? Simply Wall St.
Nov-07-19 08:15AM	Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Misses Revenue Estimates Zacks
07:00AM	Concert Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Company Update Business Wire
Nov-06-19 07:00AM	Concert Pharmaceuticals to Host KOL Webcast Event Focused on CTP-692 and Schizophrenia Business Wire
Nov-05-19 01:36PM	Concert Pharmaceuticals Inc (CNCE) Is Burning These Hedge Funds Insider Monkey
Oct-31-19 10:35AM	Analysts Estimate Concert Pharmaceuticals (CNCE) to Report a Decline in Earnings: What to Look Out for Zacks
07:00AM	Concert Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 7, 2019 Business Wire
Oct-12-19 03:15AM	Concert Pharmaceuticals Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at EADV Congress Business Wire
Oct-02-19 07:00AM	Concert Pharmaceuticals to Provide Overview of Clinical Pipeline at Cantor Healthcare Conference Business Wire
Sep-27-19 11:48AM	Concert stock falls 36 percent on Alzheimer's drug trial failure American City Business Journals -36.68%
Sep-23-19 07:00AM	Concert Pharmaceuticals Names Jeffrey Munsie as Chief Legal Officer Business Wire
Sep-19-19 10:32AM	Did You Manage To Avoid Concert Pharmaceuticals's (NASDAQ:CNCE) 20% Share Price Drop? Simply Wall St.
Sep-17-19 07:00AM	Concert Pharmaceuticals Completes Enrollment in Second Open Label Trial of CTP-543 to Evaluate Once-Daily vs. Twice-Daily Dosing in Patients with Alopecia Areata Business Wire
Sep-12-19 07:00AM	Concert Pharmaceuticals Announces CTP-543 Phase 2 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2019 EADV Congress Business Wire
Aug-29-19 07:00AM	Concert Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Aug-27-19 12:17AM	Edited Transcript of CNCE earnings conference call or presentation 1-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-16-19 03:10PM	What You Must Know About Concert Pharmaceuticals, Inc.'s (NASDAQ:CNCE) Beta Value Simply Wall St.
Aug-06-19 05:12AM	Concert Pharmaceuticals, Inc. (CNCE) Q2 2019 Earnings Call Transcript Motley Fool
Aug-01-19 09:25AM	Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Misses Revenue Estimates Zacks +8.75%
Jul-25-19 07:00AM	Concert Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 1, 2019 Business Wire
Jul-05-19 03:12PM	Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Insiders Increased Their Holdings Simply Wall St.
Jun-13-19 05:05PM	Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I Zacks +6.47%
Jun-12-19 07:00AM	Concert Pharmaceuticals Reports Positive Results from Phase 1 Studies Evaluating CTP-692 in Healthy Volunteers Business Wire
Jun-05-19 07:00AM	Concert Pharmaceuticals Completes Enrollment in Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata Business Wire
May-28-19 02:13PM	Edited Transcript of CNCE earnings conference call or presentation 2-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-16-19 07:00AM	Concert Pharmaceuticals Announces Initiation of New Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata Business Wire
May-14-19 07:00AM	Concert Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
May-07-19 01:51PM	Why Concert Pharmaceuticals, Inc.'s (NASDAQ:CNCE) CEO Pay Matters To You Simply Wall St.
May-02-19 11:52AM	Concert Pharmaceuticals, Inc. (CNCE) Q1 2019 Earnings Call Transcript Motley Fool
08:01AM	Concert: 1Q Earnings Snapshot Associated Press
07:00AM	Concert Pharmaceuticals Reports First Quarter 2019 Financial Results Business Wire
Apr-29-19 07:00AM	Concert Pharmaceuticals Names Jesper Høiland to its Board of Directors Business Wire
Apr-25-19 10:34AM	Earnings Preview: Concert Pharmaceuticals (CNCE) Q1 Earnings Expected to Decline Zacks
07:00AM	Concert Pharmaceuticals to Report First Quarter 2019 Financial Results on May 2, 2019 Business Wire
Apr-11-19 09:46AM	Concert Pharma Initiates Early-Stage Schizophrenia Study Zacks
07:00AM	Concert Pharmaceuticals to Present CTP-543 Phase 2 Interim Data in Alopecia Areata at 2019 World Congress for Hair Research Annual Meeting Business Wire
Apr-10-19 06:30AM	Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia Business Wire
Apr-08-19 03:09PM	Concert Pharmaceuticals' stock takes a sharp dive after disappointing patent appeal board ruling MarketWatch -15.71%
02:45PM	Concert Pharmaceuticals Announces Decision from Patent Trial and Appeal Board in IPR Proceeding Business Wire
Mar-25-19 10:42AM	New Strong Sell Stocks for March 25th Zacks -7.41%
Mar-12-19 08:13AM	New Strong Sell Stocks for March 12th Zacks
07:00AM	Concert Pharmaceuticals to Present at Upcoming Oppenheimer Healthcare Conference Business Wire
Mar-07-19 08:40AM	Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed Zacks
Mar-06-19 07:00AM	Concert Pharmaceuticals Announces Initiation of Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata Business Wire
Mar-05-19 04:09PM	Edited Transcript of CNCE earnings conference call or presentation 28-Feb-19 1:30pm GMT Thomson Reuters StreetEvents +5.42%
Mar-01-19 07:00AM	Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata during Late-Breaker Session at American Academy of Dermatology Annual Meeting Business Wire
Feb-28-19 10:49AM	Concert Pharmaceuticals, Inc. (CNCE) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:00AM	Concert Pharmaceuticals Reports Year Ended 2018 Financial Results and Provides Update on Clinical Programs Business Wire
Feb-21-19 07:00AM	Concert Pharmaceuticals to Report Full Year 2018 Results on February 28, 2019 Business Wire
Feb-13-19 07:36AM	Concert Pharmaceuticals, Inc. (NASDAQ:CNCE): Time For A Financial Health Check Simply Wall St.
Feb-12-19 08:00AM	Analysis: Positioning to Benefit within Masco, Ascena Retail Group, Leidos, NetScout, MYR Group, and Concert Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-11-19 07:00AM	Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting Business Wire
Feb-05-19 02:25PM	Mizuho's 9 Best Biotech Stocks to Buy for 2019 Kiplinger
Jan-24-19 07:00AM	Concert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia Business Wire
Jan-22-19 07:00AM	Concert Pharmaceuticals Completes Enrollment of 12 mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata Business Wire
Jan-02-19 08:55AM	How Much Are Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Insiders Spending On Buying Shares? Simply Wall St. +8.13%
Dec-19-18 11:39PM	Do Hedge Funds Love Concert Pharmaceuticals Inc (CNCE)? Insider Monkey
Dec-17-18 07:00AM	Concert Pharmaceuticals Initiates Phase 1 Clinical Program of CTP-692 for the Treatment of Schizophrenia Business Wire
Nov-28-18 08:41AM	Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed Zacks +9.71%
Nov-26-18 11:36AM	Should You Be Concerned About Concert Pharmaceuticals Incs (NASDAQ:CNCE) Historical Volatility? Simply Wall St.
Nov-12-18 08:45AM	Report: Exploring Fundamental Drivers Behind Sterling Construction, Tredegar, j2 Global, Medical Transcription Billing, Concert Pharmaceuticals, and Senseonics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire -21.61%
07:00AM	Concert Pharmaceuticals Reports Positive CTP-543 Results from Interim Analysis of Phase 2a Trial in Patients with Alopecia Areata Business Wire
Nov-07-18 07:00AM	Concert Pharmaceuticals to Participate at Upcoming Investor Conferences Business Wire
Nov-06-18 03:25PM	Edited Transcript of CNCE earnings conference call or presentation 1-Nov-18 12:30pm GMT Thomson Reuters StreetEvents
Nov-05-18 04:01PM	Concert Pharmaceuticals Presents Preclinical Data on CTP-692, a Novel Drug Candidate for Schizophrenia, Supporting Potential to Improve Safety Profile of D-Serine Business Wire +11.69%
Nov-01-18 08:38AM	Concert: 3Q Earnings Snapshot Associated Press

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stuart Nancy	Chief Operating Officer	Jun 22	Option Exercise	3.79	21,238	80,492	167,924	Jun 24 09:02 AM
Stuart Nancy	Chief Operating Officer	Jun 22	Sale	11.34	10,295	116,694	157,629	Jun 24 09:02 AM
Tung Roger D	Chief Executive Officer	Mar 13	Option Exercise	3.79	14,601	55,338	752,758	Mar 16 07:23 AM
Auchincloss Thomas G	Director	Mar 12	Buy	8.52	1,500	12,773	6,500	Mar 13 12:19 PM
Auchincloss Thomas G	Director	Feb 03	Buy	10.91	1,000	10,910	5,000	Feb 04 11:30 AM
Stuart Nancy	Chief Operating Officer	Dec 04	Option Exercise	4.41	5,896	26,001	104,739	Dec 06 04:05 PM
Tung Roger D	Chief Executive Officer	Dec 04	Option Exercise	4.41	13,166	58,062	644,686	Dec 06 04:05 PM
van Heek Christi	Director	Oct 08	Buy	5.90	5,000	29,504	10,000	Oct 10 08:58 AM
HUTT PETER BARTON	Director	Aug 08	Option Exercise	4.41	3,539	15,607	7,963	Aug 12 04:00 PM
HUTT PETER BARTON	Director	Aug 08	Sale	10.31	3,539	36,487	4,424	Aug 12 04:00 PM
van Heek Christi	Director	Aug 02	Buy	10.84	5,000	54,203	5,000	Oct 10 08:58 AM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience